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Background: Glucose intolerance and cardiovascular complications are major symptoms in patients with diabetes.
Many therapies have proven beneficial in treating diabetes in animals by protecting the cardiovascular system and
increasing glucose utilization. In this study, we evaluated the effects of caffeic acid phenethyl amide (CAPA) on
glucose homeostasis and vascular function in streptozotocin (STZ)-induced type 1 diabetic rats.
Methods: Diabetes (blood glucose levels > 350 mg/dL), was induced in Wistar rats by a single intravenous injection
of 60 mg/kg STZ. Hypoglycemic effects were then assessed in normal and type 1 diabetic rats. In addition, coronary
blood flow in Langendorff-perfused hearts was evaluated in the presence or absence of nitric oxide synthase (NOS)
inhibitor. The thoracic aorta was used to measure vascular response to phenylephrine. Finally, the effect of chronic
treatment of CAPA and insulin on coronary artery flow and vascular response to phenylephrine were analyzed in
diabetic rats.
Results: Oral administration of 0.1 mg/kg CAPA decreased plasma glucose in normal (32.9 ± 2.3% decrease,
P < 0.05) and diabetic rats (11.8 ± 5.5% decrease, P < 0.05). In normal and diabetic rat hearts, 1–10 μM CAPA
increased coronary flow rate, and this increase was abolished by 10 μM NOS inhibitor. In the thoracic aorta, the
concentration/response curve of phenylephrine was right-shifted by administration of 100 μM CAPA. Coronary
flow rate was reduced to 7.2 ± 0.2 mL/min at 8 weeks after STZ-induction. However, 4 weeks of treatment with
CAPA (3 mg/kg, intraperitoneal, twice daily) started at 4 weeks after STZ induction increased flow rate to 11.2 ± 0.5
mL/min (P < 0.05). In addition, the contractile response induced by 1 μM phenylephrine increased from 6.8 ± 0.6
mN to 11.4 ± 0.4 mN (P < 0.05) and 14.9 ± 1.4 mN (P < 0.05) by insulin (1 IU/kg, intraperitoneal) or CAPA treatment,
respectively.
Conclusions: CAPA induced hypoglycemic activity, increased coronary blood flow and vascular response to
phenylephrine in type 1 diabetic rats. The increase in coronary blood flow may result from endothelial NOS
activation. However, the detailed cellular mechanisms need to be further evaluated.
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Diabetes is a metabolic disease resulting from defects in
insulin secretion and/or insulin action and is often asso-
ciated with increased risk of coronary heart disease [1].
Therefore, treating diabetes involves more than glycemic
control. Chronic complications are important in diabetes
and include nephropathy, neuropathy, retinopathy, and
cardiovascular disease [2], with cardiovascular disease,
including vascular complications [3] and cardiovascular
autonomic neuropathy [4], being the major cause of
morbidity and mortality in diabetic patients [5]. In
addition, cardiovascular disease is the primary cause of
death in patients with either type 1 or type 2 diabetes
[6,7]. Patients with type 1 diabetes also bear an increased
risk of coronary heart disease, and have a higher mortal-
ity from ischemic heart disease at all ages compared to
the general population [2]. Therefore, development of
therapeutic agents with anti-diabetic and cardiovascular
protective activity is urgently required.
To evaluate the pharmacological efficacy of anti-
diabetic agents, acute or chronic diabetes has been in-
duced in animal models, such as by chemical, surgical,
and genetic manipulation [8]. Streptozotocin (STZ) is
the most frequently used drug to induce diabetes and
has been useful for the study of multiple aspects of the
disease [9]. In the cardiovascular system, studies have
shown decreased basal coronary arterial flow in STZ-
induced diabetic mice [10], decreased aortic blood flow
in STZ-induced diabetic rats [11], and decreased sensi-
tivity to phenylephrine of vascular tissues in type 1 dia-
betic rats [12]. In addition, nitric oxide (NO) production
is reduced in STZ-induced diabetes, and the decrease in
NO may be related to the pathogenesis of diabetic endo-
thelial damage [13]. Normalization of NO synthase ac-
tivity in type 1 diabetic rats prevents endothelial
dysfunction in STZ-induced animals [14]. In long-term
STZ-induced diabetic rats, the capacity of the endothe-
lium to synthesize or release NO may decrease and dis-
turb the sensitivity of vascular contractile response to
phenylephrine [15].
Currently, effective therapeutic options exist to restore
responsiveness to insulin in type 2 diabetes; however, in-
sulin therapy is not only necessary for type 1 diabetes,
but also for type 2 diabetes. Most patients with type 2
diabetes will eventually need insulin to achieve diabetes
control [16]. Insulin deficiency is a common problem in
both type 1 and type 2 diabetes [1]. Therefore, in our
study, we used STZ-induced diabetic rats to mimic the
clinical state of insulin deficiency and to evaluate new
therapeutic agents.
Caffeic acid phenethyl ester (CAPE) is the major
component in extracts of propolis and possesses anti-
inflammatory [17], anti-viral [18], cancer cell inhibitory
[19], anti-bacterial, and free radical scavenging activities[20]. CAPE can improve oxidative stress in diabetic rat
hearts [21] and exert its vasorelaxation effect on aorta
of rats in vitro (pEC50, 4.99 ± 0.19; Emax, 100.75 ±
1.65%,) [22]. Oral administration of CAPE (30 mg/kg)
for 12 weeks ameliorated the atherosclerosis progress
in apolipoprotein E-deficient mice [23]. In addition, in-
traperitoneally injected CAPE (10 μM) 1 h before re-
perfusion attenuated ischemia-reperfusion injury by
exerting antioxidant activity in Wistar rats [24]. CAPE
significantly decreased the fasting blood levels of
glucose, alanine aminotransferase, cholesterol, and tri-
glyceride induced by diabetes [25]. Several natural
products exhibit powerful glucose lowering activity,
such as caffeic acid [26], extracts of propolis from north
China [27], extracts of propolis from Brazil [28], capsa-
icin [29], and curcumin [30].
Recently, a CAPE analogue, caffeic acid phenethyl
amide (CAPA), with amide linkage between caffeic acid
and phenethyl group that resists hydrolysis in the circu-
lation, was found to be more stable compared to CAPE
in rat plasma [31] and to possess cytoprotective effects
against H2O2-induced cell death in human umbilical
vascular endothelial cells [32]. In addition, CAPA has
shown α-glucosidase inhibitory effects in yeast [33],
adiponectin productive activity in 3T3-L1 cells [34], as
well as antihyperglycemic activity and cardioprotection
effects in diabetic mice [10,35]. It also attenuates car-
diac dysfunction in abdominal aortic banding-induced
cardiac hypertrophy [36], indicating that CAPA may
be beneficial to treat diabetes and cardiovascular
complications.
The aim of this study was to characterize the acute effect
of CAPA on vascular function and glucose homeostasis in
normal and type 1 diabetic rats. In addition, the chronic ef-
fect of CAPA on vascular dysfunction of type 1 diabetic rats
was investigated and compared to that of insulin.
Methods
Compound
To synthesize CAPA (Figure 1), a solution of benzotriazol-
1-yloxytris (dimethylamino) phosphonium hexafluorophosphate
(1.2 equiv) in dichloromethane (CH2Cl2) (5 mL) was
added to a mixture of caffeic acid (100 mg), R-NH2 (1.2
equiv), and triethylamine (0.08 mL) in dimethylformamide
(1.0 mL). The mixture was stirred at 0°C for 30 min and
then at room temperature for 12 h. This reaction mixture
was evaporated under vacuum, and the residue was
partitioned between ethyl acetate (AcOEt) and H2O. The
AcOEt layer was washed with 3 N aqueous HCl and 10%
NaHCO3 (aq), dried over MgSO4, and vacuum concen-
trated. The residue was further purified by column chroma-
tography using an eluting solution (CH2Cl2-AcOEt 1:1, v/v)
on silica gel (70–230 and 230–400 mesh, Merck 7734). The
final products (82–88% yield) were recrystallized from
Figure 1 The structures of CAPE and CAPA, and the synthetic process of CAPA. CAPA was obtained from the amide binding coupling
method, beginning with caffeic acid. CAPA: R=−(CH2)2Ph. benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate (BOP),
dichloromethane (CH2Cl2), triethylamine (Et3N), dimethylformamide (DMF).
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magnetic resonance (NMR) spectra were recorded on a
Bruker Avance 500 spectrometer, electron impact mass
spectra were determined on a Finnigan TSQ-46C mass
spectrometer, and infrared spectra were recorded on a
NicoletMagna-IR 550 spectrophotometer. CAPA was
obtained from R substitution with -(CH2)2Ph. CAPA:
solid; melting point 148–149°C. Infrared νmax (cm
-1):
3288, 1642, 1591, 1523, 1361, 1279, 1036, 975, 849. 1H
NMR (CD3COCD3, 500 MHz): δ 2.84 (2H, t, J = 6.8 Hz),
3.53 (2H, q, J = 6.8 Hz), 6.43 (1H, d, J = 15.2 Hz), 6.83
(1H, d, J = 8.1 Hz), 6.92 (1H, dd, J = 8.1, 1.8 Hz), 7.07 (1H,
d, J = 1.8 Hz), 7.15–7.30 (5H, m), 7.35 (1H, br s, -NH), 7.43
(1H, d, J = 15.2Hz), 8.20 (1H, s,-OH), 8.42 (1H,
s,-OH). EI-MS m/z (%): 283 (M+, 17), 178 (22), 163 (100).
Chemicals
STZ, pentobarbital, Nω-nitro-L-arginine methyl ester
(L-NAME), methylene blue, phenylephrine, and
dimethylsulfoxide (DMSO) were purchased from Sigma-
Aldrich, USA. The inhibitor of NO-sensitive guanylyl cy-
clase, ODQ (1H-[1,2,4] Oxadiazolo [4,3-a] quinoxalin-1
-one) was purchased from Tocris Bioscience, USA. The
chemicals for the physiological solution were purchased
from J.T. Baker, Capital Scientific Inc. and Wako Pure
Chemical Industries, Japan. Insulin (Insulin Zinc Sus-
pension, Monotard® HM 100 IU/mL) was purchased
from Novo Nordisk A/S, Denmark.
Animals
We used 8-week-old male Wistar rats weighing 250–300
g (bred in a Lab animal center, National Taiwan Univer-
sity, Taiwan) for evaluation of hypoglycemic activity,insulin secretion activity, glucose tolerance test, meas-
urement of coronary arterial flow rate, aortic contractile
response, and induction of diabetes. All animal proce-
dures were performed according to the Guide for the
Care and Use of Laboratory Animals of the National In-
stitutes of Health, as well as the guidelines of the Animal
Welfare Act, and the animal studies were approved
with a certificate number 20110073 by the Institutional
Animal Care and Use Committee of the College of
Medicine, National Taiwan University. For induction
of diabetes, rats were anesthetized with sodium pento-
barbital (30 mg/mL), after a 72-h fast [37] and adminis-
tered STZ (freshly dissolved in sterile, non-pyrogenic
0.9% NaCl solution in a volume of 1 mL/kg body weight)
intravenously through the tail vein at a single dose (60
mg/kg) [38]. Two weeks after STZ injection, animals
were considered to have type 1 diabetes if they had
plasma glucose levels higher than 350 mg/dL and other
diabetic features, such as polyuria, polydipsia, and hyper-
phagia [39].
Effect of CAPA on plasma glucose in normal and STZ-
induced diabetic rats
We administered CAPA (suspended in distilled water in
a volume of 1 mL/kg body weight) orally by gavage to
overnight-fasted rats at different doses of 0.1 mg/dL, 0.5
mg/dL, and 1 mg/dL (n = 4 to 11). In a previous study,
rats that received sodium pentobarbital showed no
changes in plasma glucose [40]. Thus, under anesthesia
with sodium pentobarbital (30 mg/kg intraperitoneal),
blood samples (0.2 mL) were collected from the femoral
vein to measure plasma glucose levels. The blood sam-
ples were centrifuged at 1000 g for 5 min, and 10 μL of
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cose kit (Biosystems S.A., Barcelona, Spain). We then
estimated the levels of plasma glucose by a spectropho-
tometer (BTS-330, Biosystems S.A., Barcelona, Spain),
run in duplicate [41]. The time course of the effect of
CAPA on plasma glucose in STZ-induced diabetic rats
was preliminarily determined; the plasma glucose-
lowering effect of CAPA at an oral dosage of 0.5 mg/kg
reached a plateau within 90 min and was maintained
until 120 min. Thus, we measured the plasma glucose
decreasing effects of CAPA using blood samples col-
lected 90 min after oral administration. For the control
group, animals were orally administered the same vol-
ume of distilled water used in CAPA suspension.
Effects of CAPA on insulin secretion
We measured plasma insulin levels using an insulin en-
zyme linked immunosorbent assay (ELISA) kit (Rat In-
sulin ELISA; Mercodia AB, Uppsala, Sweden) [42].
Briefly, 8-week-old Wistar rats (250–300 g body weight,
n = 8) were anesthetized with sodium pentobarbital (30
mg/kg intraperitoneal), and blood samples (0.2 mL) were
collected from the femoral vein, centrifuged at 1000 g
for 5 min and 10 μL of clear supernatant serum was
used to measure plasma insulin levels. After completing
the ELISA test procedure, we estimated the levels of in-
sulin using a spectrophotometer (Victor3, PerkinElmer
Inc., MA, USA); samples were run in duplicate.
Effect of CAPA on intravenous glucose tolerance test
For the intravenous glucose tolerance test, overnight
fasted rats were anesthetized with sodium pentobarbital
(30 mg/kg intraperitoneal). We administered CAPA (0.5
mg/mL/kg) in a volume of 1 mL/kg body weight (n = 6)
or the same volume of distilled water (vehicle treatment,
n = 8) 30 minutes before intravenous injection of glu-
cose (1 g/kg body weight) and measured the blood glu-
cose level at 5, 10, 20, 40, 60, 90, and 120 min after
glucose injection [43].
Effect of CAPA on coronary arterial flow rate in
Langendorff-perfused hearts
The rats were anesthetized with sodium pentobarbital
(50 mg/kg) and given heparin (300 IU/kg) intraperitone-
ally. The Langendorff-perfused heart model, using a con-
stant perfusion pressure instead of constant flow rate,
was employed [44]. Hearts were rapidly excised and
immersed in perfusion medium. After excision of the
heart from the chest, the aorta was cannulated and per-
fused at 80 mmHg with perfusate containing 119.7 mM
NaCl, 23.8 mM NaHCO3, 5.0 mM KCl, 0.3 mM
NaH2PO4, 1.2 mM CaCl2, 1.1 mM MgCl2, and 5.6 mM
glucose. The perfusate was equilibrated with 95% O2, 5%
CO2 at 37°C. Perfusion pressure and flow rate (mL/min)were monitored by a MLT844/D pressure transducer
(Capto, Horten, Norway), and electrocardiogram was
digitally measured during the period of the experiment
by a data acquisition device (PowerLab, ADInstruments,
Castle Hill, Australia). The 2 tips of the ventricular re-
cording electrode were separated and placed on opposite
sides of the ventricular epicardium to generate a bipolar
transcardiac electrogram. RR intervals were measured as
the average of 6 consecutive cycles to calculate the heart
rate as beats per minute [45].
Effect of CAPA on thoracic aorta
We used the thoracic aorta of rats for vascular contrac-
tion response studies. The thoracic aorta were cleaned
of adhering periadventitial fat, cut into 3-mm length
rings, and then incubated in an organ bath containing
Kreb’s buffer (composition [in mM]: NaCl 118.2, KCl
4.7, KH2PO4 1.2, NaHCO3 25, MgSO4 1.2, CaCl2 1.9,
and glucose 11.7), with a pH of 7.4, and gassed with 95%
O2 and 5% CO2. The aortic rings were mounted to a
polygraph (model RS 3400 recorder, Gould), and con-
traction force was monitored by a pressure transducer
(Type BG 25; Gould, Oxnard, Calif., USA). Aortic rings
were equilibrated at a resting tension of 2 g for 1 h be-
fore the experiments [46]. We evaluated the relaxation
effect of CAPA on endothelium-intact and endothelium-
denuded aorta, pre-constricted with phenylephrine 1 μM
or KCl 80 mM. Contractile responses were generated by
addition of incremental concentrations of phenylephrine
(0.001 μM to 10 μM) on endothelium-denuded aortic
rings. The intactness or absence of endothelium was con-
firmed by the relaxant responses to acetylcholine (1 μM)
in rings precontracted with phenylephrine 1 μM [47].
Vascular effects of CAPA chronic treatment on STZ-
induced diabetic rats
A previous study demonstrated that STZ-induced dia-
betic mice expressed early vascular dysfunction [48], in-
creased blood glucose stability, and decreased E/A flow
ratio [49] after 4 weeks of STZ-induction. We therefore
started the therapeutic regimen from this time point (4
weeks). There were 3 treatment groups of diabetic rats:
vehicle-treated group (0.1 mL/kg DMSO), insulin-
treated group (1 IU/kg insulin), and CAPA-treated group
(3 mg/kg CAPA). All groups were administered the
agents intraperitoneally twice daily for 4 weeks. The
control group consisted of age- and sex-matched normal
Wistar rats.
Data analysis
Values are expressed as means ± SEM of n observations,
where n represents the number of animals studied. The
data were subjected to ANOVA followed by a multiple-
comparison test (Bonferroni’s test) or analyzed by
Table 2 Effect of CAPA on plasma insulin levels in normal
rats
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1 7.7 ± 1.0 14.9 ± 3.4* 8
Plasma insulin was measured at 30 min after oral administration of CAPA
(1 mg/kg) in overnight fasted rats. Data (mean ± SEM) were obtained from 8
animals. *P < 0.05 compared with the pre-treatment animals and examined by
the paired t-test.Results
CAPA decreased plasma glucose levels in normal and
STZ-induced diabetic rats
The effect of CAPA on plasma glucose levels was mea-
sured in anesthetized overnight-fasted rats. The max-
imum plasma glucose lowering effect was observed at
90 minutes after oral administration of 0.1 mg/kg CAPA
(n = 7) compared to vehicle treatment (n = 8) (percent
decrease in glucose level, 32.9 ± 2.3% vs. 5.8 ± 5.7%, P <
0.05) (Table 1). The plasma glucose lowering effect of
CAPA in normal rats was not dose dependent (32.8 ±
3.4%, n = 6 and 29.5 ± 1.7%, n = 6 after oral administra-
tion of 0.5 mg/kg and 1 mg/kg CAPA, respectively). Ob-
vious plasma glucose lowering activity was observed
after oral administration of 0.1 mg/kg CAPA in STZ-
induced type 1 diabetic rats (11.8 ± 5.5%, n = 4, P < 0.05
compared to vehicle treatment, 0.6 ± 0.1%, n = 8). No
further increase in plasma glucose lowering activity was
observed when the dose was increased to 0.5 mg/kg and
1.0 mg/kg (13.8 ± 4.3%, n = 7 and 11.6 ± 1.7%, n = 11,
respectively).CAPA increased insulin secretion
Insulin secretion was measured in overnight fasted and
anesthetized rats. Plasma insulin concentration increased
after 30 minutes from a mean value of 7.7 ± 1.0 μIU/mL
to 14.9 ± 3.4 μIU/mL (n = 8) after oral administration of
1 mg/kg CAPA (Table 2).CAPA improved glucose tolerance
The plasma glucose levels of CAPA (0.5 mg/kg)-treated
rats (n = 6) were 112.2 ± 4.3, 100.5 ± 3.6, 91.7 ± 2.1, and
93.2 ± 2.7 mg/dL at 40, 60, 90, and 120 minutes after
intravenous glucose (1000 mg/kg) injection, respectively;
these levels were significantly (P < 0.05) lower than those











Vehicle 138.5 ± 5.9 129.3 ± 2.2 5.8 ± 5.7
0.1 124.3 ± 4.6 83.1 ± 3.7 * 32.9 ± 2.3 *
0.5 120.5 ± 5.3 81.0 ± 5.7 * 32.8 ± 3.4 *
1 126.2 ± 2.0 89.0 ± 3.2 * 29.5 ± 1.7 *
Plasma glucose was measured at 90 min after oral administration of vehicle or CAP
(mean ± SEM) were obtained from 4–11 animals. *P < 0.05 compared with the vehi138.0 ± 12.4 mg/dL, 155.0 ± 25.3 mg/dL, and 156.0 ±
25.7 mg/dL, respectively, n = 8, Figure 2).CAPA increased coronary arterial flow rate
Coronary arterial flow rate was measured 20 minutes
after perfusion with a solution containing 1, 3, or 10
μM CAPA. The flow rate of perfused hearts compared
to normal rats was shown to be increased by 1 μM
CAPA from 11.8 ± 1.0 mL/min to 15.6 ± 1.2 mL/min.
Furthermore, coronary arterial flow rate dose-
dependently increased to 17.4 ± 1.3 mL/min and 19.5 ±
0.7 mL/min following injection of 3 and 10 μM CAPA,
respectively (Table 3). CAPA 1, 3, and 10 μM also
increased the coronary arterial flow rate in the hearts
of STZ-induced type 1 diabetic rats from 10.3 ± 0.6
mL/min to 11.9 ± 0.9 mL/min, 13.3 ± 1.1 mL/min, and
14.8 ± 1.4 mL/min, respectively. This increase in coron-
ary arterial flow rate, however, was less than that in
normal rats. The heart rate of animals during all experi-
ments did not significantly change (Table 3). Both the
basal coronary arterial flow rate and the coronary
arterial flow rate in the presence of CAPA (1, 3, or 10
μM) in normal rats were significantly reduced by L-
NAME (10 μM), a nitric oxide synthase (NOS) inhibi-
tor, from 10.8 ± 0.8 mL/min, 13.2 ± 0.8 mL/min, 14.0 ±
1.0 mL/min, and 16.8 ± 1.2 mL/min to 5.5 ± 0.7 mL/
min, 5.8 ± 0.8 mL/min, 6.6 ± 0.7 mL/min, and 7.4 ± 0.8
mL/min, respectively (Figure 3A and normalized re-
sponse in Figure 3B). The increase in coronary arteriald diabetic rats
Type 1 diabetic rats








8 446.6 ± 11.6 444.1 ± 11.6 0.6 ± 0.1 8
7 469.8 ± 37.2 409.8 ± 37.9 11.8 ± 5.5 * 4
6 461.7 ± 21.3 394.0 ± 13.5 * 13.8 ± 4.3 * 7
6 447.4 ± 25.5 393.7 ± 20.6 * 11.6 ± 1.7 * 11
A in overnight fasted rats. Rats treated with vehicle were used as controls. Data
cle control group and examined by the paired t-test.
Figure 2 The effect of CAPA on the glucose tolerance test.
Intravenous glucose tolerance tests (IVGTT) were performed in
anesthetized fasted animals. Rats were orally administered CAPA (0.5
mg/mL/kg, n = 6) or the same volume of distilled water (vehicle,
n = 8) at 30 minutes before intravenous injection of glucose (1000
mg/kg). Blood glucose levels were measured before and at 5, 10, 20,
40, 60, 90, and 120 min after glucose injection. (●) CAPA-treated
group: CAPA (0.5 mg/mL/kg, p.o. 30 min before glucose intravenous
injection). (○) Vehicle-treated group: Rats treated with vehicle at the
same volume were used as controls. Data are presented as the
mean ± SEM. *P < 0.05 compared with the vehicle.
Figure 3 Effect of CAPA on coronary arterial flow rate in
normal or L-NAME-treated rat hearts. Coronary arterial flow rate
(mL/min) was measured after 30 min of equilibrium with retrograde
perfusion using a constant pressure of 80 mmHg. The L-NAME-
treated hearts were perfused with 10 μM L-NAME (A), and data
were normalized to basal flow rate (B). Data (mean ± SEM) were
obtained from 4–9 animals. *P < 0.05 compared with the untreated
control of normal rat hearts and #P < 0.05 compared with the
untreated control of the L-NAME group.
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10 μM L-NAME.
CAPA relaxed the thoracic aorta and shifts the dose–
response curve of Phenylephrine-induced contraction
CAPA showed concentration-dependent inhibition of
endothelium-intact and endothelium-denuded rat thor-
acic aorta, constriction induced by 80 mM potassium or
1 μM phenylephrine (Figure 4A and Figure 4B). These
vasorelaxant effects precontracted with phenylephrine
were not affected by 10 μM NOS inhibitor (L-NAME),
10 μM NO-sensitive guanylyl cyclase selective inhibitor
(ODQ), or 100 μM soluble guanylyl cyclase inhibitorTable 3 Effect of CAPA on the coronary arterial flow rate and heart rate
CAPA
(μM)
Normal rat hearts Type 1 diabetic rat hearts
Coronary arterial flow rate (mL/min) Heart rate (BPM) n Coronary arterial flow rate (mL/min) Heart rate (BPM) n
0 11.8 ± 1.0 236.1 ± 7.1 5 10.3 ± 0.6 207.8 ± 12.9 9
1 15.6 ± 1.2 * 234.2 ± 11.7 5 11.9 ± 0.9 * 208.5 ± 11.1 9
3 17.4 ± 1.3 * 234.1 ± 6.5 5 13.3 ± 1.1 * 203.2 ± 9.2 8
10 19.5 ± 0.7 * 218.0 ± 5.5 4 14.8 ± 1.4 * 205.5 ± 10.2 6
Effect of CAPA on the coronary arterial flow rate (mL/min) and heart rate (BPM: beats per minute) in normal and type 1 diabetic rat hearts. Coronary arterial flow
rate was measured after 30 min of equilibrium with retrograde perfusion at a constant pressure of 80 mmHg. Data (mean ± SEM) were obtained from 4–9
animals. *P < 0.05 compared with CAPA (0 μM)-administered animals.
Figure 4 Concentration-dependent inhibition of CAPA on thoracic aorta, constriction-induced by high concentration potassium or
phenylephrine. The relaxation effect of CAPA was measured in endothelium-intact (+EC) and endothelium-denuded (−EC) thoracic aorta. The
aortic strips were pre-constricted with high concentration of potassium (80 mM) (A) or 1 μM phenylephrine (B), pre-treated with inhibitors (C),
such as 10 μM NOS inhibitor (L-NAME), 10 μM nitric oxide-sensitive guanylyl cyclase selective inhibitor (ODQ), and 100 μM soluble guanylyl
cyclase inhibitor (MB), and CAPA was added in a cumulated concentrations in the organ bath to assess relaxation effects. The IC50 values for
CAPA are shown in (D). Data (mean ± SEM) were obtained from 6–8 animals.
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ition of vasoconstriction are shown in Figure 4D, with
no significant differences seen among them. The
concentration-response curve of endothelium-denuded
aortic strips to phenylephrine demonstrated a significant
right shift (Figure 5A and normalized response in
Figure 5B), and the EC50 of phenylephrine was signifi-
cantly increased by 100 μM CAPA (EC50 = 347.7 ± 120.9
nM) (Figure 5C); the Hill coefficient of phenylephrine-
induced contraction remained unchanged (Figure 5D).CAPA attenuated the progression of vascular dysfunction
in STZ-induced diabetic rats
Compared to a coronary arterial flow rate of 12.6 ± 0.5
mL/min (n = 6) in control normal rats, the mean flow
rate in diabetic rats at 8 weeks after STZ induction was
reduced to 7.2 ± 0.2 mL/min (n = 4, P < 0.05). However,
twice daily treatment with CAPA (3 mg/kg, intraperito-
neal) in diabetic rats (n = 5, started at 4 weeks after STZ
induction) for 4 weeks significantly increased coronary
arterial flow rate to 11.2 ± 0.5 mL/min (P < 0.05 com-
pared with STZ-vehicle treatment) (Figure 6A). In
addition, the contractile force induced by 1 μM phenyl-
ephrine was significantly decreased in the STZ-vehicle
group (from 13.2 ± 0.9 mN to 6.8 ± 0.6 mN, n = 4, P <
0.05), but increased from 6.8 ± 0.6 mN to 11.4 ± 0.4 mN(n = 4) and 14.9 ± 1.4 mN (n = 6) by insulin or CAPA
treatment, respectively (P < 0.05 compared with STZ-
vehicle treatment) (Figure 6B).Discussion
CAPA was found to decrease plasma glucose levels in
normal and diabetic rats. Decreased plasma glucose
levels in normal rats are associated with both enhance-
ment of insulin secretion and glucose utilization. Several
pharmacological agents such as KATP channel inhibitors
[50], Glucagon-like peptide-1 and dipeptidyl peptidase
IV (DPP-IV) inhibitors [51], are known to exert their
hypoglycemic action via enhancement of insulin release.
In a previous study, we tested the effect of CAPA on
DPP-IV activity and KATP potassium current in a pancre-
atic beta cell line, MIN6. CAPA did not inhibit DPP-IV
activity, but was found to inhibit KATP channels with a
calculated IC50 of 21.2 μM (data not shown). Since the
calculated maximal plasma concentration after oral ad-
ministration of CAPA at 0.5 mg/kg is less than 1.8 μM,
the stimulation of insulin secretion after oral administra-
tion can only partly be attributed to its inhibition of
KATP channels. In addition, in the present study, CAPA
was found to inhibit α-adrenergic receptors on vascular
tissue. Since inhibition of sympathetic α-adrenergic re-
ceptors is reported to enhance insulin release [52], the
Figure 5 Effect of CAPA on concentration-dependent contractile response to phenylephrine in endothelium-denuded aortic strips. The
effect of CAPA on the contractile response to phenylephrine was measured in endothelium-denuded thoracic aorta. The aortic strips were pre-
treated with 1, 10 and 100 μM CAPA, and phenylephrine was added in a cumulative dose in the organ bath (A). Normalized contraction to the
maximum response of phenylephrine is shown (B). The EC50 values for phenylephrine and the Hill coefficient are shown in (C) and (D). Data
(mean ± SEM) were obtained from 6–8 animals. *P < 0.05 compared with the vehicle, DMSO pre-treatment group.
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tributed to inhibition of α-adrenoceptors. In STZ-
induced type 1 diabetic rats, CAPA lowered plasma glu-
cose levels even though this diabetic rat model has low
insulin secretion activity, suggesting that insulin-
independent mechanisms may be involved. Our findings
were concordant with those studies that reported plasma
glucose lowering activity of CAPA in STZ-induced type
1 diabetic mice [35] and increased glucose transporter 4
protein expression along with insulin-induced glycogen
synthesis in diet-induced type 2 diabetic mice [10]. The
detailed mechanism responsible for the antidiabetic ac-
tivity in type 1 diabetic rats remains to be investigated.
Diabetes is associated with several cardiovascular risk
factors, such as abnormal glycemia, lipidemia, visceral
obesity, and oxidative stress, which impair endothelial
function and predispose patients to macrovascular dis-
ease, including coronary artery disease and cerebral vas-
cular disease, ultimately the major causes of morbidity
and mortality in diabetic patients [2]. A previous study
showed that CAPA has cytoprotective effects on human
umbilical vein endothelial cells [32]. In the present
study, we found that 1 and 3 μM CAPA increased cor-
onary blood flow in a Langendorff-perfused heart model.
In addition, we observed that the CAPA-inducedincrease in coronary blood flow was prevented by an
NOS inhibitor. Our results suggest that CAPA may en-
hance coronary blood flow by increasing the availability
or level of NO.
Our results suggest that CAPA may enhance coronary
flow by increasing the availability of NO in the coronary
artery. The 2,2-diphenyl-1-picrylhydrazyl radical scaven-
ging activity of CAPA, as shown by an EC50 of 18.6 ± 3.2
μM (comparable to the EC50 of 15.6 ± 2.0 μM of CAPE,
data not shown), may reduce tissue oxidative stress and
increase tissue availability of NO. In addition, our studies
in type 2 diabetic mice show that CAPA treatment could
increase manganese superoxide dismutase in fat tissue
[10], but whether this effect occurs in the coronary vascu-
lar bed remains unknown.
Higher concentrations of CAPA were found to relax the
thoracic aorta following potassium- or phenylephrine-
induced constriction. None of the inhibitors of the NO
signaling pathway was able to block the vasorelaxant ac-
tivity of CAPA (Figure 4), but the concentration-response
curve to phenylephrine was shifted to the right in the
presence of CAPA (Figure 5), suggesting that high concen-
trations of CAPA may have α-receptor blocking activity.
Because of the relatively low α-adrenergic receptor
blocking activity of CAPA, no changes in blood pressure
Figure 6 Effect of chronic treatment with CAPA and insulin on
the vascular response. (A) The basal coronary arterial flow rate
(mL/min) in retrograde-perfused hearts was measured to evaluate
the effect of CAPA in type 1 diabetic rats. The animals were divided
into 4 groups and intraperitoneally administered CAPA twice daily
for 4 weeks. Control: age- and sex-matched normal rats, n = 6.
STZ-veh: vehicle-treated diabetic rats, 0.1 mL/kg DMSO, n = 4.
STZ-insulin: insulin-treated diabetic rats, 1 IU/kg, n = 4. STZ-CAPA:
CAPA-treated diabetic rats, 3 mg/kg, n = 5. *,#P < 0.05 compared
with control groups and STZ-induced diabetic rats treated with
vehicle. (B) Effect of CAPA on the phenylephrine-induced aortic
constriction of type 1 diabetic rat aorta. The effect of CAPA on
the phenylephrine-induced aortic contraction response (mN) of
STZ-induced type 1 diabetic rat thoracic aorta was measured in
isolated aortic strips. The animals were divided into 4 groups.
Control: age- and sex-matched normal rats, n = 4. STZ-veh: vehicle-
treated diabetic rats, 0.1 mL/kg DMSO, n = 4. STZ-Ins: insulin-treated
diabetic rats, 1 IU/kg, n = 4. STZ-CAPA: CAPA-treated diabetic rats, 3
mg/kg, n = 6. *,#P < 0.05 compared with control and STZ-veh groups.
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CAPA in the tail cuff plethysmography experiment (data
not shown).
With regard to potassium-induced thoracic aorta con-
striction, CAPA administration relaxed denuded thoracic
aorta as shown by an IC50 of approximately 75 μM. In
endothelium-intact thoracic aorta, CAPA relaxed the
thoracic aorta with an IC50 of 45 μM. This finding sug-
gests that enhancement of endothelium-dependent NO
production may contribute to the relaxant effect ofCAPA in endothelium-intact aorta. The relaxant effect
of CAPA on potassium-induced constriction in denuded
aorta may be mediated by direct inhibition of L-type
Ca2+ channels in smooth muscle. However, this remains
to be investigated.
This study showed that CAPA has potent plasma glu-
cose lowering and coronary artery dilation effects with-
out influencing heart rate and blood pressure. We found
decreased plasma glucose levels and increased coronary
dilation in CAPA-treated rats; whether CAPA-enhanced
vasodilation occurs in blood vessel flow through other
tissues remains unknown.
STZ-induced diabetic rats showed decreased auto-
nomic activity and coronary artery perfusion [53]. Our
study strongly suggests that CAPA is a powerful candi-
date for treating vascular disease in diabetic patients.
Conclusions
CAPA, a compound derived from CAPE, the active
component in propolis, shows more structural stability
than CAPE and lowers plasma glucose levels and exerts
coronary artery dilation effects in normal and diabetic
rats. CAPA also ameliorates vascular dysfunction in dia-
betic rats, suggesting that it could be a good candidate
for the treatment of vascular complications in diabetic
patients. Since the major complication in diabetes is cardio-
vascular dysfunction, further studies on cardiac functions,
such as on the contractile response in cardiomyocytes,
in vivo cardiac hemodynamic function, and underlying mo-
lecular mechanisms are required.
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